Created by potrace 1.16, written by Peter Selinger 2001-2019
beatandraise
beta
Latest Financials
Filings:
By Category
By Date
Search Filings
Institutional Holders
beta
Earnings Transcripts
beta
Global Search
Company Exhibits:
Indentures
Material Contracts & Credit Agreements
Plans of Reorganization
Articles and Bylaws
Underwriting Agreements
SEC Edgar
MeiraGTx Holdings plc
SIC 2836 · Biological Products (No Diagnostic Substances)
Notes
Support
about
terms
Created by potrace 1.16, written by Peter Selinger 2001-2019
beatandraise.com
Created by potrace 1.16, written by Peter Selinger 2001-2019
beatandraise.com
beta
Latest Financials
Filings:
Category
Date
Search Filings
Institutional Holders
beta
Earnings Transcripts
beta
Global Search
SEC Edgar
MeiraGTx Holdings plc
SIC 2836 · Biological Products (No Diagnostic Substances)
Notes
Support
about
terms
Created by potrace 1.16, written by Peter Selinger 2001-2019
beatandraise.com
beta
Latest Financials
Filings:
Category
Date
Search Filings
Institutional Holders
beta
Earnings Transcripts
beta
Global Search
SEC Edgar
MeiraGTx Holdings plc
SIC 2836 · Biological Products (No Diagnostic Substances)
Notes
Support
about
terms
$
MGTX
MeiraGTx Holdings plc
CIK:
0001735438
|
SEC Filings
Income Statement
Cash Flow
Balance Sheet
v3.26.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) - USD ($)
$ in Thousands
3 Months Ended
6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Total revenue
$ 321,434
$ 3,691
$ 321,727
$ 5,617
Operating expenses:
General and administrative
12,013
12,313
20,941
21,677
Research and development
57,832
33,495
89,816
66,275
Total operating expenses
77,009
48,484
118,119
92,006
Income (loss) from operations
244,425
(44,793)
203,608
(86,389)
Other non-operating income (expense):
Foreign currency (loss) gain
(1,466)
8,624
(4,303)
12,311
Interest income
706
408
895
1,379
Interest expense
(3,509)
(3,034)
(6,357)
(6,077)
Loss on derivative liability
(5,223)
(5,223)
Loss on equity method investee
(71,902)
(71,902)
Income tax expense
(2,362)
(2,362)
Net income (loss)
160,669
(38,795)
114,356
(78,776)
Net income (loss) attributed to:
Net Income (Loss)
160,720
(38,795)
114,407
(78,776)
Net loss attributed to non-controlling interest
(51)
(51)
Net income (loss)
160,669
(38,795)
114,356
(78,776)
Other comprehensive gain (loss):
Foreign currency translation gain (loss) attributed to shareholders
677
(2,459)
849
(3,806)
Foreign currency translation loss attributed to non-controlling interest
(4)
(4)
Comprehensive income (loss)
$ 161,342
$ (41,254)
$ 115,201
$ (82,582)
Basic net income (loss) per ordinary share
$ 1.76
$ (0.48)
$ 1.32
$ (0.99)
Diluted net income (loss) per ordinary share
$ 1.71
$ (0.48)
$ 1.3
$ (0.99)
Weighted-average number of ordinary shares outstanding, basic
91,418,527
80,585,625
86,387,685
79,813,273
Weighted-average number of ordinary shares outstanding, diluted
93,805,296
80,585,625
88,115,023
79,813,273
Related party
Operating expenses:
Cost of service revenue
$ 5,763
$ 2,676
$ 5,961
$ 4,054
Non-related party
Operating expenses:
Cost of service revenue
1,401
1,401
Service revenue
Total revenue
11,885
11,885
Service revenue - related party
Total revenue
104,906
$ 3,691
105,199
$ 5,617
License revenue - related party
Total revenue
$ 204,643
$ 204,643
v3.26.1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Cash flows from operating activities:
Net income (loss)
$ 114,356
$ (78,776)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Share-based compensation expense
7,433
10,551
Foreign currency loss (gain)
4,303
(12,311)
Depreciation and amortization
5,831
6,271
Change in right-of-use assets
1,264
5,133
Gain on termination of lease liabilities
(1,365)
Loss (gain) on disposal of equipment, furniture and fixtures
46
(122)
Undistributed losses of equity method investee
71,902
Amortization of interest on asset retirement obligations
74
98
Amortization of debt discount
663
552
Non-cash consideration received from related party - revenue arrangement
(104,988)
Loss on derivative liability
5,223
Acquired in-process research and development
27,728
(Increase) decrease in operating assets:
Accounts receivable
(3,180)
Accounts receivable - related party
(2,818)
(1,653)
Unbilled receivables - related party
(24,365)
Contract assets - related party
986
Prepaid expenses
2,039
144
Tax incentive receivable
437
4,851
Other current assets
(25,015)
1,516
Other assets, net
71
Increase (decrease) in operating liabilities:
Accounts payable
611
(2,968)
Accrued expenses
(12,842)
(12,595)
Lease liabilities
(1,906)
(5,271)
Corporate tax liability
2,362
Other current liabilities
(39,606)
5,904
Deferred revenue
361
Deferred revenue - related party
(50,711)
(1,720)
Net cash used in operating activities
(20,727)
(80,775)
Cash flows from investing activities:
Purchase of property, plant and equipment
(2,340)
(2,944)
Acquisition of in-process research and development assets
(24,228)
Proceeds from sale of non-controlling interest
674
Proceeds from sale of equipment, furniture and fixtures
473
Net cash used in investing activities
(25,894)
(2,471)
Cash flows from financing activities:
Exercise of share options
828
35
Payments of withholdings on shares withheld for income taxes
(5,960)
(2,761)
Payments on lease obligations - financing leases
(29)
Proceeds from the issuance of ordinary shares
128,207
9,915
Issuance costs in connection with ordinary shares
(6,074)
(26)
Payment for treasury shares
(18,193)
Contributions from non-controlling interest
3
Payment of notes payable
(75,000)
Proceeds from royalty notes payable
100,000
Net cash provided by financing activities
123,782
7,163
Net increase (decrease) in cash, cash equivalents and restricted cash
77,161
(76,083)
Effect of exchange rate changes on cash, cash equivalents and restricted cash
12
4,839
Cash, cash equivalents and restricted cash at beginning of the period
68,193
105,668
Cash, cash equivalents and restricted cash at end of the period
145,366
34,424
Supplemental disclosure of non-cash transactions:
Non-cash contribution for acquisition of in-process research and development
3,263
Issuance of shares in connection with a license agreement
249
Fixed asset acquisitions included in accounts payable and accrued expenses
61
892
Issuance costs in connection with sale of ordinary shares in accounts payable and accrued expenses at end of period
793
Supplemental disclosure of cash flow information:
Cash paid for interest
$ 7,888
$ 5,557
v3.26.1
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Jun. 30, 2026
Dec. 31, 2025
CURRENT ASSETS:
Cash and cash equivalents
$ 143,166
$ 65,931
Unbilled receivables - related party
24,364
Prepaid expenses
3,989
6,017
Tax incentive receivable
14,286
15,286
Other current assets
26,928
1,527
Total Current Assets
218,347
91,761
Property, plant and equipment, net
100,333
105,465
Intangible assets, net
421
578
Restricted cash
2,200
2,262
Other assets
1,362
1,147
Equity method and other investments
39,838
6,749
Right-of-use assets - operating leases, net
11,524
12,852
Right-of-use assets - finance leases, net
22,424
23,616
TOTAL ASSETS
396,449
244,430
CURRENT LIABILITIES:
Accounts payable
11,668
10,066
Accrued expenses
21,225
32,893
Lease obligations - operating leases, current
2,260
2,851
Lease obligations - finance leases, current
40
38
Note payable, net, current
24,648
Corporate tax liability
2,362
Other current liabilities
15,106
50,283
Total Current Liabilities
58,096
122,555
Deferred revenue - related party
11,101
65,120
Lease obligations - operating leases
9,936
11,351
Lease obligations - finance leases
85
109
Asset retirement obligations
1,450
1,399
Note payable, net
100,000
49,689
TOTAL LIABILITIES
180,668
250,223
COMMITMENTS AND CONTINGENCIES (Note 13)
SHAREHOLDERS' EQUITY (DEFICIT):
Ordinary Shares, $0.00003881 par value, 1,288,327,750 authorized, 94,188,118 and 81,120,931 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively
3
3
Capital in excess of par value
932,323
808,021
Treasury shares
(18,193)
Accumulated other comprehensive gain
3,255
2,406
Accumulated deficit
(701,816)
(816,223)
Non-controlling interest
209
Total Shareholders' Equity (Deficit)
215,781
(5,793)
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT)
396,449
244,430
Related party
CURRENT ASSETS:
Accounts receivable
2,438
3,000
CURRENT LIABILITIES:
Deferred revenue
5,076
$ 1,776
Non-related party
CURRENT ASSETS:
Accounts receivable
3,176
CURRENT LIABILITIES:
Deferred revenue
$ 359